Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk

This study has been completed.
Information provided by (Responsible Party):
University of Wisconsin, Madison Identifier:
First received: February 5, 2009
Last updated: December 5, 2014
Last verified: December 2014

Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have greater mammographic density.

Condition Phase
Breast Cancer Risk
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Characterize the distribution of total xenoestrogen burden and identify important source of xenoestrogen exposure among a clinic-based sample of postmenopausal women. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate the association of total xenoestorgen exposure with mammographic density. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum Xenoestrogen

Enrollment: 270
Study Start Date: July 2008
Study Completion Date: April 2010
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   55 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Subjects recruited from screening mammography population


Inclusion Criteria:

  • 55-70 years of age, Post menopausal

Exclusion Criteria:

  • If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00839696

United States, Wisconsin
University of Wisconsin Hospital
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Principal Investigator: Amy Trentham Dietz, PhD Associate Professor- Population Health Sciences, UW School of Medicine and Public Health
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison Identifier: NCT00839696     History of Changes
Other Study ID Numbers: CC07104
Study First Received: February 5, 2009
Last Updated: December 5, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Wisconsin, Madison:

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on February 27, 2015